Online Only Articles

Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels

UC San Diego Moores Cancer Center, San Diego, CA
Mayo Clinic, Scottsdale, AZ, USA
UC San Diego Moores Cancer Center, San Diego, CA
Mayo Clinic, Scottsdale, AZ, USA
Mayo Clinic, Scottsdale, AZ, USA
UC San Diego Moores Cancer Center, San Diego, CA
UC San Diego Moores Cancer Center, San Diego, CA
UC San Diego Moores Cancer Center, San Diego, CA
UC San Diego Moores Cancer Center, San Diego, CA
UC San Diego Moores Cancer Center, San Diego, CA;Mayo Clinic, Scottsdale, AZ, USA
Vol. 105 No. 1 (2020): January, 2020 https://doi.org/10.3324/haematol.2018.212597